Igor Puzanov, MD, MSCI, FACP

The next frontier, according to Igor Puzanov, MD, MSCI, FACP, includes improving immune toxicity recognition and long-term care.

From cardiovascular risk to missed toxicity grading, Igor Puzanov, MD, MSCI, outlines what is failing in checkpoint inhibitor toxicity management.

ASCO 2026 clinicians highlighted unmet needs from navigating complex treatment decisions and overcoming translation gaps, to optimizing regimens.

Updated toxicity criteria improve immunotherapy toxicity management in melanoma, spotlighting rapid action for rare cardiotoxicity, says Igor Puzanov, MD, MSCI, FACP.